The effect of inflammation on coagulation and vice versa

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 273-278

  Van Der Poll, Tom ^a,b,c,d   De Boer, Johannes Daan D ^a,c   Levi, Marcel ^d  

^a Center of Experimental and Molecular Medicine   (Netherlands)

^b Department of Infectious Diseases Tropical Medicine and AIDS   (Netherlands)

^c Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

activated protein C; coagulation; inflammation; protease activated receptors; tissue factor

Indexed keywords

ACTIVATED PROTEIN C; CD11B ANTIGEN; CD18 ANTIGEN; ENDOTHELIAL PROTEIN C RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THROMBIN; THROMBOPLASTIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; ENDOTOXEMIA; HUMAN; INFECTION; INFLAMMATION; MORTALITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

BLOOD COAGULATION DISORDERS; COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 79955524498     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328344c078     Document Type: Article

References (36)

1. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2 Suppl):S26-34.
2. Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008; 111:1208-1216. (Pubitemid 351213402)
3. Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticles: a new player in sepsis? Crit Care 2010; 14: 236.
4. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83:536-545. (Pubitemid 351966862)
5. Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004; 103:1342-1347. (Pubitemid 38168646)
6. Pawlinski R, Wang JG, Owens AP 3rd, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 2010; 116:806-814.
7. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16:887-896.
8. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23:821-852. (Pubitemid 40563186)
9. Taylor F, Chang A, Ferrell G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78:357-363.
10. Laudes IJ, Chu JC, Sikranth S, et al. Antic5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160:1867-1875. (Pubitemid 34525666)
11. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010; 116:1002-1010.
12. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood 2009; 114:2367-2374.
13. van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care 2008; 12 (Suppl 6):S3.
14. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115:1121-1130.
15. Taylor FB Jr, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925. (Pubitemid 17050920)
16. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95:1680-1686. (Pubitemid 30120829)
17. Shpacovitch V, Feld M, Hollenberg MD, et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008; 83:1309-1322. (Pubitemid 351960309)
18. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol 2010; 160:191-203.
19. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005; 280:19808-19814. (Pubitemid 41379506)
20. Russo A, Soh UJ, Paing MM, et al. Caveolae are required for proteaseselective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A 2009; 106:6393-6397.
21. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeabilityenhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909-3916. (Pubitemid 350248446)
22. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178-3184.
23. Singleton PA, Moreno-Vinasco L, Sammani S, et al. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37:222-231. (Pubitemid 47255005)
24. Niessen F, Furlan-Freguia C, Fernandez JA, et al. Endogenous EPCR/aPCPAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood 2009; 113:2859-2866
25. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C. J Exp Med 2007; 204:2439-2448. (Pubitemid 47529328)
26. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120:1971-1980.
27. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8? dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120:3167-3178.
28. Zheng X, Li W, Song Y, et al. Nonhematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost 2007; 5:1394-1400. (Pubitemid 46965366)
29. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009; 113:4078-4085.
30. Nick JA, Coldren CD,Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-3885. (Pubitemid 39620133)
31. Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452:654-658. (Pubitemid 351483355)
32. Kaneider NC, Leger AJ, Agarwal A, et al. ?Role reversal? for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007; 8:1303-1312. (Pubitemid 350131169)
33. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15:1318-1321.
34. Levi M, Lowenberg E, Meijers JC. Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost 2010; 36:550-557.
35. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
36. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341. (Pubitemid 41362701)